Cullinan Amber

Cullinan Amber is a clinical-stage biotechnology company and a subsidiary of Cullinan Therapeutics, focused on developing novel immunotherapies for cancer. The company's lead program, CLN-619, is a first-in-class monoclonal antibody designed to stimulate both innate and adaptive immune responses by stabilizing MICA/B on the surface of tumor cells. By preventing the shedding of these ligands, CLN-619 promotes tumor recognition and destruction by NK cells and T cells. The program is currently being evaluated in Phase 1/2 clinical trials for patients with advanced solid tumors, both as a monotherapy and in combination with checkpoint inhibitors. As a program-specific entity within Cullinan's hub-and-spoke model, Cullinan Amber benefits from centralized management and shared resources while maintaining a dedicated focus on its primary asset.